Macrogenics (FRA:M55) Marketable Securities : €7.9 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Macrogenics's Marketable Securities for the quarter that ended in Mar. 2025 was €7.9 Mil.

Macrogenics's annual Marketable Securities increased from Dec. 2022 (€42.9 Mil) to Dec. 2023 (€118.2 Mil) but then declined from Dec. 2023 (€118.2 Mil) to Dec. 2024 (€18.0 Mil).

Macrogenics Marketable Securities Historical Data

The historical data trend for Macrogenics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Marketable Securities Chart

Macrogenics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

75.13

106.33

42.92

118.16

17.98

Macrogenics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															95.57	52.43	18.69	17.98	7.93

Macrogenics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Macrogenics (FRA:M55) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Macrogenics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Macrogenics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Macrogenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

MGNX:USA

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Macrogenics Headlines

No Headlines